Skip to main content
Erschienen in: Clinical Drug Investigation 11/2006

01.11.2006 | Case Report

Onset of Liver Damage after a Single Administration of Infliximab in a Patient with Refractory Ulcerative Colitis

verfasst von: Dr Enzo Ierardi, Nicola Della Valle, Maurizio Cosimo Nacchiero, Vincenzo De Francesco, Giuseppe Stoppino, Carmine Panella

Erschienen in: Clinical Drug Investigation | Ausgabe 11/2006

Einloggen, um Zugang zu erhalten

Abstract

We report the case of a patient with refractory ulcerative colitis who developed cholestatic acute liver damage after a single infusion of infliximab. Unusual aspects of this case were the early onset (after the first administration) of liver damage and the absence of antinuclear antibodies, alcohol intake, hepatotoxic drugs and all known viral and metabolic causes of hepatic injury. Moreover, no serological or morphological findings of primary sclerosing cholangitis were observed. The patient’s liver damage resolved spontaneously within 6 weeks. Although a direct relationship between administration of infliximab and onset of acute liver damage could not be definitely established, our case suggests that infliximab may induce direct liver damage, the course of which is similar to acute cholestatic hepatitis and resolves following withdrawal of the drug.
Literatur
1.
Zurück zum Zitat Germano V, Picchianti Diamanti A, Baccano G, et al. Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann Rheum Dis 2005; 64: 1519–20PubMedCrossRef Germano V, Picchianti Diamanti A, Baccano G, et al. Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann Rheum Dis 2005; 64: 1519–20PubMedCrossRef
2.
Zurück zum Zitat Esteve M, Saro C, Gonzalez-Huix F, et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis. Gut 2004; 53: 1363–5PubMedCrossRef Esteve M, Saro C, Gonzalez-Huix F, et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis. Gut 2004; 53: 1363–5PubMedCrossRef
3.
Zurück zum Zitat Schiemann U, Kellner H. Gastrointestinal side effects in the therapy of rheumatologic diseases. Z Gastroenterol 2002; 40: 937–43PubMedCrossRef Schiemann U, Kellner H. Gastrointestinal side effects in the therapy of rheumatologic diseases. Z Gastroenterol 2002; 40: 937–43PubMedCrossRef
4.
Zurück zum Zitat Saleem G, Li SC, MacPherson BR, et al. Hepatitis with interface inflammation and IgG, IgM, and IgA anti-double-stranded DNA antibodies following infliximab therapy: comment on the article by Charles et al. Arthritis Rheum 2001; 44: 1966–8PubMedCrossRef Saleem G, Li SC, MacPherson BR, et al. Hepatitis with interface inflammation and IgG, IgM, and IgA anti-double-stranded DNA antibodies following infliximab therapy: comment on the article by Charles et al. Arthritis Rheum 2001; 44: 1966–8PubMedCrossRef
5.
Zurück zum Zitat Mastroianni A, Minutilli E, Mussi A, et al. Cytokine profiles during infliximab monotherapy in psoriatic arthritis. Br J Dermatol 2005; 153: 531–6PubMedCrossRef Mastroianni A, Minutilli E, Mussi A, et al. Cytokine profiles during infliximab monotherapy in psoriatic arthritis. Br J Dermatol 2005; 153: 531–6PubMedCrossRef
6.
Zurück zum Zitat Feletar M, Brockbank JE, Schentag CT, et al. Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients. Ann Rheum Dis 2004; 63: 156–61PubMedCrossRef Feletar M, Brockbank JE, Schentag CT, et al. Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients. Ann Rheum Dis 2004; 63: 156–61PubMedCrossRef
7.
Zurück zum Zitat Tobon GJ, Cañas C, Jaller JJ, et al. Serious liver disease induced by infliximab. Clin Rheumatol. Epub 2006 Mar 18 Tobon GJ, Cañas C, Jaller JJ, et al. Serious liver disease induced by infliximab. Clin Rheumatol. Epub 2006 Mar 18
8.
Zurück zum Zitat Garcia Aparicio AM, Rey JR, Sanz AH, et al. Successful treatment with etanercept in a patient with hepatotoxicity closely related to infliximab. Clin Rheumatol. Epub 2006 Mar 21 Garcia Aparicio AM, Rey JR, Sanz AH, et al. Successful treatment with etanercept in a patient with hepatotoxicity closely related to infliximab. Clin Rheumatol. Epub 2006 Mar 21
9.
Zurück zum Zitat Jarret S, Cunnane G, Conaghan P, et al. Anti-tumor necrosis factor-α therapy-induced vasculitis: case series. J Rheumatol 2003; 30: 2287–91 Jarret S, Cunnane G, Conaghan P, et al. Anti-tumor necrosis factor-α therapy-induced vasculitis: case series. J Rheumatol 2003; 30: 2287–91
10.
Zurück zum Zitat Vujanovic NL, Polimeno L, Azzarone A, et al. Changes of liver-resident NK cells during liver regeneration in rats. J Immunol 1995; 154: 6324–38PubMed Vujanovic NL, Polimeno L, Azzarone A, et al. Changes of liver-resident NK cells during liver regeneration in rats. J Immunol 1995; 154: 6324–38PubMed
11.
Zurück zum Zitat Schwab M, Klotz U. Pharmacokinetic considerations in the treatment of inflammatory bowel disease. Clin Pharmacokinet 2001; 40: 723–51PubMedCrossRef Schwab M, Klotz U. Pharmacokinetic considerations in the treatment of inflammatory bowel disease. Clin Pharmacokinet 2001; 40: 723–51PubMedCrossRef
12.
Zurück zum Zitat Danan G, Benichou C, Begaud B, et al. Criteria of imputation of acute hepatitis to a drug: results of consensus meetings. Gastroenterol Clin Biol 1987; 11: 581–5PubMed Danan G, Benichou C, Begaud B, et al. Criteria of imputation of acute hepatitis to a drug: results of consensus meetings. Gastroenterol Clin Biol 1987; 11: 581–5PubMed
Metadaten
Titel
Onset of Liver Damage after a Single Administration of Infliximab in a Patient with Refractory Ulcerative Colitis
verfasst von
Dr Enzo Ierardi
Nicola Della Valle
Maurizio Cosimo Nacchiero
Vincenzo De Francesco
Giuseppe Stoppino
Carmine Panella
Publikationsdatum
01.11.2006
Verlag
Springer International Publishing
Erschienen in
Clinical Drug Investigation / Ausgabe 11/2006
Print ISSN: 1173-2563
Elektronische ISSN: 1179-1918
DOI
https://doi.org/10.2165/00044011-200626110-00008

Weitere Artikel der Ausgabe 11/2006

Clinical Drug Investigation 11/2006 Zur Ausgabe